MANE Veradermics Incorporated

Subscribe to $MANE

Veradermics Incorporated

Subscribe to $MANE

$MANE

Biotechnology: Pharmaceutical Preparations

Health Care

IPO Year: 2026

Exchange: NYSE

Recent Analyst Ratings for Veradermics Incorporated

Date	Price Target	Rating	Analyst

See more ratings

Veradermics Incorporated Press Releases

Fastest customizable press release news feed in the world

View All

NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell

NYSE issues a pre-market daily advisory direct from the trading floor. NEW YORK, Feb. 12, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. Ashley Mastronardi delivers the pre-market update on February 12th Markets are higher after mixed reactions to yesterday's hotter than expected Jobs Report as the Bureau of Labor Statistics reported that the U.S. economy added 130,000 jobs.Forgent Power Solutions (NYSE:FPS) is celebrating its early February IPO this morning with shares having jumped 22% since trading

2/12/26 8:55:00 AM ET

$FPS

$ICE

$MANE

Industrial Machinery/Components

Energy

Investment Bankers/Brokers/Service

Finance

Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss

This marks the completion of enrollment of all male Phase 3 studies of VDPHL01 in pattern hair loss, with approximately 1,000 male patients enrolled across studies Topline data from initial '302' trial anticipated in the first half of 2026; '304' confirmatory study topline data anticipated in the second half of 2026 VDPHL01, if approved, has the potential to be the first and only non-hormonal oral FDA approved treatment for men and women with pattern hair loss, a condition affecting an estimated 50 million men and 30 million women in the United States Veradermics, Incorporated (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing

2/9/26 7:30:00 AM ET

$MANE

Biotechnology: Pharmaceutical Preparations

Health Care

Veradermics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering

Veradermics, Incorporated ("Veradermics"), (NYSE:MANE) a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for common aesthetic and dermatological conditions, today announced the closing of its previously announced upsized initial public offering of 17,339,294 shares of its common stock at an initial public offering price of $17.00 per share, including 2,261,647 shares sold pursuant to the exercise in full of the underwriters' option to purchase additional shares. The gross proceeds from the offering were approximately $294.8 million, before deducting underwriting discount and commissions and estimated offering expenses. All o

2/5/26 4:05:00 PM ET

$MANE

Biotechnology: Pharmaceutical Preparations

Health Care

Veradermics Incorporated

Recent Analyst Ratings for Veradermics Incorporated

Veradermics Incorporated

Recent Analyst Ratings for Veradermics Incorporated

Veradermics Incorporated Insider Purchases

Director Suvretta Capital Management, Llc bought $10,542,478 worth of shares (282,674 units at $37.30) (SEC Form 4)

Director Coric Vlad converted options into 638,262 shares and bought $1,999,982 worth of shares (117,646 units at $17.00), increasing direct ownership by 913% to 129,939 units (SEC Form 4)

Director Childs John W converted options into 1,907,889 shares and bought $4,999,989 worth of shares (294,117 units at $17.00) (SEC Form 4)

Large owner Longitude Capital Partners V, Llc converted options into 3,578,873 shares and bought $18,275,000 worth of shares (1,075,000 units at $17.00) (SEC Form 4)

Director Enright Patrick G converted options into 3,578,873 shares and bought $18,275,000 worth of shares (1,075,000 units at $17.00) (SEC Form 4)

Veradermics Incorporated Insider Trading

Director Suvretta Capital Management, Llc bought $10,542,478 worth of shares (282,674 units at $37.30) (SEC Form 4)

New insider Suvretta Capital Management, Llc claimed ownership of 3,886,317 shares (SEC Form 3)

SEC Form 4 filed by Director Pance Katarina

Director Grant-Kels Jane M. converted options into 2,455 shares (SEC Form 4)

SEC Form 4 filed by Director Friedman David Matthew

Director Coric Vlad converted options into 638,262 shares and bought $1,999,982 worth of shares (117,646 units at $17.00), increasing direct ownership by 913% to 129,939 units (SEC Form 4)

Director Childs John W converted options into 1,907,889 shares and bought $4,999,989 worth of shares (294,117 units at $17.00) (SEC Form 4)

Large owner Longitude Capital Partners V, Llc converted options into 3,578,873 shares and bought $18,275,000 worth of shares (1,075,000 units at $17.00) (SEC Form 4)

Director Enright Patrick G converted options into 3,578,873 shares and bought $18,275,000 worth of shares (1,075,000 units at $17.00) (SEC Form 4)

SEC Form 4 filed by General Counsel Greco Michael V.

Veradermics Incorporated Press Releases

NYSE Content Update: Forgent Power Solutions, Post IPO, to Ring Opening Bell

Veradermics Completes Enrollment in Second Pivotal Phase 3 Clinical Trial of VDPHL01 for Male Pattern Hair Loss

Veradermics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering

Veradermics Incorporated SEC Filings

SEC Form SCHEDULE 13D filed by Veradermics Incorporated

SEC Form S-8 filed by Veradermics Incorporated

Veradermics Incorporated filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits